Cryotherapy & Oxaliplatin

Launched by NYU LANGONE HEALTH · Feb 21, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring whether cryotherapy, a treatment that involves applying extreme cold, can help prevent a common side effect called peripheral neuropathy in patients with stage III colon cancer who are starting chemotherapy with a drug called oxaliplatin. Peripheral neuropathy can cause tingling, pain, and numbness in the hands and feet, which can be quite uncomfortable for patients undergoing treatment.

To be eligible for this study, participants must be over 18, diagnosed with stage III colon cancer, and not have received chemotherapy before. They should also be planning to start a specific chemotherapy regimen called Capecitabine + Oxaliplatin (often shortened to CAPOX). However, individuals with certain conditions, such as diabetes or pre-existing nerve damage, cannot participate. If you join the trial, you’ll receive cryotherapy alongside your chemotherapy, and the study will help researchers learn more about how effective this approach can be in protecting against nerve damage during treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Over the age of 18 years
• • Willingness to participate in research
• • Diagnosed with stage III colon cancer
• • Chemotherapy naïve
• • Planning to initiate Capecitabine + Oxaliplatin (CAPOX) chemotherapy regimen as part of standard of care.
• Exclusion Criteria:
• • Pre-existing peripheral neuropathy
• • Pre-existing diabetes
• • Raynaud's disease
• • Metabolic syndrome, including: Hypertension; Hypercholesterolemia; and Obesity (BSA \> 2)
• • Upper extremity amputees
• • Specific autoimmune diseases: Guillain-Barre; Lupus; Rheumatoid arthritis; and Sjogren's syndrome